NCT05429905 2023-03-09Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaKK Women's and Children's HospitalPhase 1/2 Unknown48 enrolled
NCT03636685 2018-08-17Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLCChineseAMSPhase 1/2 Unknown60 enrolled